中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续

智通财经2025-06-19

中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续国内丙类目录及商保政策有望推动估值继续提升。2）医药投融资有望复苏：二级市场繁荣有望带来一级市场投融资回升CXO及上游景气度向好。3）医疗器械有望触底回升：招投标数据已开始回暖以旧换新积压需求逐步释放。4）医疗服务增速有望迎拐点：全国DRG/DIP支付改革实现统筹区及符合条件...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2544181977?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-19 08:26","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2544181977","market":"hk","top_or_hot":-1,"title":"中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续","media":"智通财经","content":"<div>\n<p>中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续国内丙类目录及商保政策有望推动估值继续提升。2）医药投融资有望复苏：二级市场繁荣有望带来一级市场投融资回升CXO及上游景气度向好。3）医疗器械有望触底回升：招投标数据已开始回暖以旧换新积压需求逐步释放。4）医疗服务增速有望迎拐点：全国DRG/DIP支付改革实现统筹区及符合条件...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-19 08:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续国内丙类目录及商保政策有望推动估值继续提升。2）医药投融资有望复苏：二级市场繁荣有望带来一级市场投融资回升CXO及上游景气度向好。3）医疗器械有望触底回升：招投标数据已开始回暖以旧换新积压需求逐步释放。4）医疗服务增速有望迎拐点：全国DRG/DIP支付改革实现统筹区及符合条件...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1147","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2544181977","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544181977","pubTimestamp":1750292766,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续国内丙类目录及商保政策有望推动估值继续提升。2）医药投融资有望复苏：二级市场繁荣","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159883":"医疗器械","159938":"医药","159992":"创新药","161027":"证券","601881":"中国银河","BK1147":"投资银行业与经纪业","DIP":"BTD CAPITAL FUND","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK7095":"多种金属与采矿","BK1564":"中资券商股","09939":"开拓药业-B","BK7504":"锂钴概念","BK0188":"融资融券","BK1515":"抗疫概念","CXO":"康休","09996":"沛嘉医疗-B","CXO.AU":"CORE LITHIUM LTD","06978":"永泰生物-B","BK0276":"资本市场","BK1222":"医疗保健用品","BK1161":"生物科技","06881":"中国银河","BK1100":"医疗保健设备"},"translate_title":"China Galaxy Securities pointed out that in the second half of 2025, it will continue to be optimistic about innovative drugs and pay attention to the recovery in the growth rate of equipment and services. 1) Continue to be optimistic about pharmaceutical innovation: innovative drug BD is expected to continue in the second half of the year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1,"159938":1,"159992":1,"161027":1,"601881":1,"CXO":1,"09939":1,"DIP":1,"CXO.AU":1,"06978":1,"09997":1,"09996":1,"06881":1},"content_text":"中国银河证券指出2025年下半年继续看好创新药关注器械与服务增速回升。1）持续看好医药创新：下半年创新药BD预计仍将持续国内丙类目录及商保政策有望推动估值继续提升。2）医药投融资有望复苏：二级市场繁荣有望带来一级市场投融资回升CXO及上游景气度向好。3）医疗器械有望触底回升：招投标数据已开始回暖以旧换新积压需求逐步释放。4）医疗服务增速有望迎拐点：全国DRG/DIP支付改革实现统筹区及符合条件医疗机构全覆盖眼科领域复苏信号显现。5）医药消费静待复苏：观察国内刺激消费政策效果预期有利于医药消费复苏渠道库存出清、终端需求回暖。投资建议上2025年医药创新药板块估值修复显著下半年有望带动其他板块回暖我们看好创新药产业链、细分行业龙头关注医药消费复苏。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544181977","isCrawlerRequest":true}